Table 2.
Characteristic | All cases (n = 27) | New-onset (n = 6) | Relapse (n = 21) |
---|---|---|---|
Age (years) | |||
≤ 19 | 3 | 0 | 3 |
20–29 | 4 | 0 | 4 |
30–39 | 3 | 0 | 3 |
40–49 | 2 | 1 | 1 |
50–59 | 2 | 0 | 2 |
60–69 | 6 | 1 | 5 |
≥ 70 | 7 | 4 | 3 |
Sex | |||
Female | 12 | 2 | 10 |
Male | 15 | 4 | 11 |
Treatments before this event (multiple answers allowed) | |||
No treatment | 10 | 6 | 4 |
Oral corticosteroid | 15 | 0 | 15 |
Steroid pulse therapy | 3 | 0 | 3 |
Immunosuppressive therapy (except for rituximab) | 10 | 0 | 10 |
Rituximab | 3 | 0 | 3 |
RAS-I | 7 | 0 | 7 |
Antiplatelet drugs | 1 | 0 | 1 |
Type of the vaccine | |||
COMIRNATY Intramuscular Injection (Pfizer-BioNTech) | 23 | 5 | 18 |
COVID-19 Vaccine Moderna Intramuscular Injection (Moderna/Takeda) | 1 | 0 | 1 |
Unknown | 3 | 1 | 2 |
Vaccination dose | |||
First dose | 8 | 1 | 7 |
Second dose | 18 | 4 | 14 |
Both first and second doses | 1 | 1 | 1 |
Histopathological diagnoses revealed by the kidney biopsy | |||
Minimal change disease | 12 | 2 | 10 |
Focal segmental glomerulosclerosis | 2 | 0 | 2 |
Membranous nephropathy | 4 | 2 | 2 |
IgA nephropathy | 2 | 1 | 1 |
Membranoproliferative glomerulonephritis | 1 | 0 | 1 |
C3 glomerulopathy | 2 | 0 | 2 |
Unknown/did not answer | 4 | 1 | 3 |
Adverse reactions (multiple answers allowed) | |||
Fever (≥ 37.5 ℃) | 5 | 0 | 5 |
Fatigue | 8 | 0 | 8 |
Headache | 1 | 0 | 1 |
Chills | 0 | 0 | 0 |
Muscle pain | 6 | 2 | 4 |
Pain at the application site | 1 | 0 | 1 |
Joint pain | 2 | 0 | 2 |
None | 2 | 0 | 2 |
Unknown | 8 | 4 | 4 |
COVID-19 coronavirus disease 2019, RAS-I renin–angiotensin system inhibitor